Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

Nadofaragene firadenovec intravesical gene therapy continues to show promise in treating BCG-unresponsive NMIBC bladder cancer.

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

We recently compiled a list of the 12 Stocks Under $10 With High Upside Potential. In this article, we are going to take a ...

An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the ...

India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...

For years, medtech firms around the globe (and certainly European companies) introduced their products in Europe, which requires obtaining a CE ...

BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...